JAK Inhibitor: Research & Clinical Takeaways

For alopecia areata nonresponders to one JAK inhibitor, a trial of a different JAK inhibitor may still be effective, based on this observational...

In darker phototypes with refractory melasma, a single 755‑nm picosecond alexandrite laser session followed by topical JAK inhibition and...

In pediatric HSCT recipients, spiny folliculocentric eruptions mimicking lichen spinulosus can signal cutaneous cGVHD; exclude trichodysplasia...

In adults with severe alopecia areata, baricitinib 4 mg daily led to SALT ≤20 in 63% by 48 weeks, with adverse events in 9.4%. Real-world results...

In routine practice, oral JAK inhibitors produced meaningful repigmentation for many patients with vitiligo; extending treatment beyond 6 months was...

In older adults with psoriatic disease, IL‑12/23/17 biologics were associated with fewer serious infections, while tofacitinib was associated with...

In adolescents with moderate to severe atopic dermatitis, upadacitinib 15–30 mg daily sustained high EASI-75 responses through 76 weeks, with safety...

For dermatology patients, short-term systemic JAK/TYK2 inhibitor use did not increase MACE or VTE versus placebo over a median 16 weeks. This...

In dermatology RCTs, JAK inhibitors did not increase short-term risk of MACE, death, or VTE vs controls. Use routine cardiovascular/VTE risk...

For adolescents and adults with severe alopecia areata, oral JAK inhibitors provide meaningful regrowth for roughly 1 in 4 to 2 in 5 patients by...

For adults with AD, prioritize moisturizers and appropriate TCS or TCIs, with topical PDE‑4 or JAK inhibitors as options. Use bathing and wet wraps...

For adult atopic dermatitis, prioritize moisturizers and guideline-supported topicals (corticosteroids, calcineurin inhibitors, PDE-4 and JAK...